NBT508 is an innovative ADC drug for non-hodgkins lymphoma (NHL) (for example, diffuse large B-cell lymphoma, DLBCL), which was developed based on NewBio Therapeutics’ proprietary site-specific linker (TetraM) technology and antibody screening technology. The ADC product is highly homogeneous, with average drug/antibody ratio (DAR) around 2 and DAR2 components around 85%. This project is in clinical phase I stage.